IDXX insider filing: 5,450 shares traded; options disclosed

Rhea-AI Filing Summary

Sharon E. Underberg, EVP, General Counsel & Corporate Secretary of IDEXX Laboratories (IDXX), filed a Form 4 reporting stock and option activity on 08/08/2025 and 08/12/2025. The filing shows non-derivative and derivative transactions including an acquisition of 5,450 common shares (08/08/2025) and a same-day disposition of 5,450 common shares (08/08/2025), and an acquisition of 183 common shares (08/12/2025). The record lists beneficial ownership following the reported transactions at 6,338.6539 shares.

The Form 4 also reports derivative holdings: a non-qualified stock option covering 5,450 underlying shares (exercise price shown as $206.94) and an incentive stock option covering 183 underlying shares (exercise price shown as $544.08). The filing includes an explanatory note that 28.7090 shares were purchased under the Issuer Employee Stock Purchase Plan during March and June 2025. The form is signed by an attorney-in-fact on behalf of Ms. Underberg on 08/12/2025.

Positive

• Updated beneficial ownership reported with a clear post-transaction total of 6,338.6539 shares
• Derivative holdings disclosed showing options for 5,450 and 183 underlying shares with exercise prices noted
• ESPP purchases explicitly identified: 28.7090 shares bought on March 31 and June 30, 2025

Negative

• Disposal of 5,450 shares on 08/08/2025, which reduced direct holdings from 11,605.6539 to 6,155.6539 as shown
• Large same-day transactions (acquisition and disposition of identical 5,450-share amounts) may complicate interpretation of intent but are disclosed

Insights

Securities Analyst

TL;DR: Insider reported simultaneous buy and sell activity and option holdings; net direct beneficial ownership ends at 6,338.6539 shares.

The filing documents both acquisitions and a disposition by Sharon Underberg on 08/08/2025 and a subsequent acquisition on 08/12/2025. Material facts: a reported acquisition of 5,450 shares and a contemporaneous sale of 5,450 shares on 08/08/2025, plus a later acquisition of 183 shares, leaving 6,338.6539 shares beneficially owned. Derivative positions shown include options covering 5,450 and 183 underlying shares with stated exercise prices. For investors, these are routine Section 16 disclosures that update insider ownership and option grants; the filing does not provide additional operational or financial data.

Corporate Governance Expert

TL;DR: Disclosure complies with Section 16 reporting and documents option grants and ESPP purchases; signature provided by attorney-in-fact.

The Form 4 includes explicit explanatory notes: 28.7090 shares were acquired via the Issuer Employee Stock Purchase Plan earlier in 2025, and option grants include one that vested in installments beginning 02/14/2020 and one vested in a single installment on 02/14/2025. The filing is signed by an attorney-in-fact, which is properly indicated. There are no disclosures in this filing of litigation, pledges, or other governance events outside routine insider transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Underberg Sharon E.

(Last) (First) (Middle)

ONE IDEXX DRIVE

(Street)

WESTBROOK ME 04092

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, GC & Corporate Secretary

3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/08/2025		M		5,450	A	$206.94	11,605.6539(1)	D
Common Stock	08/08/2025		S		5,450	D	$651.6	6,155.6539	D
Common Stock	08/12/2025		M		183	A	$544.08	6,338.6539	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right-to-buy)	$206.94	08/08/2025		M			5,450	(2)	02/13/2029	Common Stock	5,450	$0	0	D
Incentive Stock Option (right-to-buy)	$544.08	08/12/2025		M			183	(3)	02/13/2031	Common Stock	183	$0	0	D

Explanation of Responses:

1. Includes a total of 28.7090 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, 2025 and June 30, 2025.

2. Grant of option to buy shares of Issuer common stock that became exercisable in four annual installments beginning on February 14, 2020.

3. Grant of option to buy shares of Issuer common stock that became exercisable in one installment on February 14, 2025.

Remarks:

	/s/ Lily J. Lu, Attorney-in-Fact for Sharon E. Underberg	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Sharon E. Underberg report on her Form 4 for IDXX?

The Form 4 reports an acquisition of 5,450 common shares and a disposition of 5,450 common shares on 08/08/2025, and an acquisition of 183 common shares on 08/12/2025.

What is Sharon Underberg's beneficial ownership of IDXX after these filings?

The filing shows total beneficial ownership following the reported transactions as 6,338.6539 shares.

Does the Form 4 disclose any stock options for Underberg?

Yes. The filing discloses a non-qualified stock option covering 5,450 underlying shares (exercise price $206.94) and an incentive stock option covering 183 underlying shares (exercise price $544.08).

Were any ESPP purchases reported on this Form 4?

Yes. The explanatory notes state a total of 28.7090 shares were purchased under the Issuer Employee Stock Purchase Plan on 03/31/2025 and 06/30/2025.

Who signed the Form 4 for Sharon Underberg?

The form is signed by Lily J. Lu, Attorney-in-Fact for Sharon E. Underberg and dated 08/12/2025.